These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32623916)

  • 21. Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.
    Depincé-Berger AE; Vergnon-Miszczycha D; Girard A; Frésard A; Botelho-Nevers E; Lambert C; Del Tedesco E; Genin C; Pozzetto B; Lucht F; Roblin X; Bourlet T; Paul S
    Retrovirology; 2016 Jun; 13(1):44. PubMed ID: 27363286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].
    Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):543.e1-43. PubMed ID: 25959461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.
    Lafeuillade A; Assi A; Poggi C; Bresson-Cuquemelle C; Jullian E; Tamalet C
    AIDS Res Ther; 2014; 11(1):33. PubMed ID: 25320633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
    Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
    J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
    HIV Med; 2001 Jan; 2(1):27-34. PubMed ID: 11737373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
    Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
    J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
    Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
    J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
    Lorenzen T; Stoehr A; Walther I; Plettenberg A
    Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent administration of IFNα14 and cART in TKO-BLT mice enhances suppression of HIV-1 viremia but does not eliminate the latent reservoir.
    Sutter K; Lavender KJ; Messer RJ; Widera M; Williams K; Race B; Hasenkrug KJ; Dittmer U
    Sci Rep; 2019 Dec; 9(1):18089. PubMed ID: 31792317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
    Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
    Minami R; Takahama S; Kaku Y; Yamamoto M
    J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pace of Coreceptor Tropism Switch in HIV-1-Infected Individuals after Recent Infection.
    Arif MS; Hunter J; Léda AR; Zukurov JPL; Samer S; Camargo M; Galinskas J; Kallás EG; Komninakis SV; Janini LM; Sucupira MC; Diaz RS
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28659473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.